Overview

Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.
Phase:
N/A
Details
Lead Sponsor:
University of Dundee
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Fluticasone
Montelukast
Salmeterol Xinafoate